Mark E Saad
Director at Axsome Therapeutics, Inc. (AXSM)
Mark E Saad has filed 18 insider reports with the SEC since March 2021, as director at Axsome Therapeutics, Inc. (AXSM). In the last 12 months Mark E Saad sold $6.21M of stock on the open market. The latest filing, on June 11, 2026, reports exercise or conversion of a derivative at Axsome Therapeutics, Inc. (AXSM).
- Filings
- 18
- Companies
- 1
- Bought on market
- $114K
- Sold on market
- $8.35M
Companies where Mark E Saad is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Director | 11,431 | $114K | $8.35M | $34.52 | $149.24+332% | Jun 11, 2026 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record. Price now: the latest daily close, against the average buy price.
Every filing
- Jun 8, 2026AXSMDirector Saad Mark E converted options into 1,429 shares, increasing direct ownership by 14% to 11,431 unitsForm 4Exercise or conversion of a derivative
- Jun 5, 2026AXSMSEC Form 4 filed by Director Saad Mark EForm 4Grant or award
- Dec 31, 2025-$6.21MAXSMDirector Saad Mark E exercised 37,577 shares at a strike of $5.46 and sold $6,206,969 worth of shares (37,577 units at $165.18)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Dec 31, 2025~$6.21MAXSMMark E Saad plans to sell 37,577 shares (~$6.21M)Form 144Planned sale10b5-1 plan
- Sep 5, 2025-$1.14MAXSMDirector Saad Mark E exercised 9,127 shares at a strike of $9.00 and sold $1,141,514 worth of shares (9,127 units at $125.07)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Sep 5, 2025~$1.14MAXSMMark E Saad plans to sell 9,127 shares (~$1.14M)Form 144Planned sale10b5-1 plan
- Jun 6, 2025AXSMSEC Form 4 filed by Director Saad Mark EForm 4Grant or award
- Feb 21, 2025AXSMSEC Form 4 filed by Director Saad Mark EForm 4Grant or award
- Sep 11, 2024-$1.01MAXSMDirector Saad Mark E exercised 11,016 shares at a strike of $3.67 and sold $1,005,871 worth of shares (11,016 units at $91.31)Form 4Exercise or conversion of a derivativeOpen-market sale10b5-1 plan
- Sep 11, 2024~$1.01MAXSMMark E Saad plans to sell 11,016 shares (~$1.01M)Form 144Planned sale10b5-1 plan
- Jun 7, 2024AXSMSEC Form 4 filed by Director Saad Mark EForm 4Grant or award
- Feb 27, 2024AXSMSEC Form 4 filed by Saad Mark EForm 4Grant or award
- Jun 2, 2023AXSMSEC Form 4 filed by Saad Mark EForm 4Grant or award
- Jun 3, 2022AXSMSEC Form 4 filed by Saad Mark EForm 4Grant or award
- Mar 4, 2022AXSMSEC Form 4 filed by Saad Mark EForm 4Grant or award
- Nov 17, 2021+$114KAXSMSEC Form 4: Saad Mark E bought $113,922 worth of shares (3,300 units at $34.52), increasing direct ownership by 43% to 10,002 unitsForm 4Open-market purchase
- Jun 4, 2021AXSMSEC Form 4 filed by Saad Mark EForm 4Grant or award
- Mar 5, 2021AXSMSEC Form 4 filed by E Mark SaadForm 4Grant or award
Compare Mark E Saad with
- Mark E Saad vs Mark L. Jacobson1 shared
- Mark E Saad vs Herriot Tabuteau1 shared
- Mark E Saad vs Roger Jeffs1 shared
- Mark E Saad vs Susan Mahony1 shared
- Mark E Saad vs Mark Coleman1 shared
- Mark E Saad vs Nick Pizzie1 shared
Other insiders at the same companies
- Mark L. JacobsonAXSM
- Herriot TabuteauAXSM
- Roger JeffsAXSM
- Susan MahonyAXSM
- Mark ColemanAXSM
- Nick PizzieAXSM
- Ari MaizelAXSM
- Hunter R. MurdockAXSM
Questions about Mark E Saad
- What is Mark E Saad's role at Axsome Therapeutics, Inc.?
- Mark E Saad reports to the SEC as director at Axsome Therapeutics, Inc. (AXSM), according to the latest filing on June 11, 2026.
- How many shares does Mark E Saad own?
- After the latest filing that states it, Mark E Saad directly owned 11,431 shares of Axsome Therapeutics, Inc. (AXSM). Shares held through trusts, funds or family members are reported separately and are not counted here.
- Has Mark E Saad bought or sold stock recently?
- The most recent open-market purchase was on November 17, 2021: bought 3,300 shares of Axsome Therapeutics, Inc. (AXSM) for $114K at an average of $34.52. The most recent open-market sale was on December 31, 2025: sold 37,577 shares of Axsome Therapeutics, Inc. (AXSM) for $6.21M at an average of $165.18.
- How do I get alerts when Mark E Saad files?
- Follow Mark E Saad on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Mark E Saad (SEC CIK 0001295913). Totals count each trade once, skipping amendments whose original is on file, from Mar 10, 2021 on. View on SEC EDGAR